Orion Group Holdings Inc ORN
News
Orion Group Holdings Appoints Mark A. Handley to Board of Directors
ORYZON to Present Updated Positive Clinical Data for Iadademstat in Hematological Malignancies at ASH 2026
Oryzon announces authorization in Spain of VIVALDI, a collaborative clinical study with CETLAM to evaluate iadademstat in combination with standard-of-care therapy in high-risk newly-diagnosed AML subpopulations
Orion Group Holdings Announces New Contract Awards of $250 Million
ORYZON to participate in upcoming events in November
Orion Group Holdings Reports Third Quarter 2026 Results
ORYZON further strengthens vafidemstat’s patent portfolio with new decisions to grant
Orion Group Holdings to Report Third Quarter 2026 Financial Results on Tuesday, October 27, 2026
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
Orion Group Holdings Announces Conference Participation
ORYZON to Participate in Upcoming Events in September and October
ORYZON Announces Notice of Allowance for U.S. Patent Application Covering Iadademstat Combination With Gilteritinib
